 |
Digoxin immune FAB (Ovine) |
|---|---|
| Trade Name | Digibind |
| Orphan Indication | Potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy |
| USA Market Approval | USA |
| USA Designation Date | 1984-11-01 00:00:00 |
| Sponsor | Glaxo Wellcome Inc.;5 Moore Drive;Research Triangle Park, North Carolina, 27709 |
